Literature DB >> 3942562

Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects.

T A Musliner, C Giotas, R M Krauss.   

Abstract

Analysis of human plasma by gradient gel electrophoresis (GGE) revealed multiple distinct bands in the size range between very low density (VLDL) and low density lipoproteins (LDL). GGE of intermediate density lipoproteins (IDL) from normal subjects consistently showed two major bands with particle diameters in the range of 275 to 300 A. The larger, usually predominant subspecies was designated IDL-1, and the smaller, IDL-2. GGE also demonstrated two sizes of subpopulations in the VLDL density range in all subjects. A discontinuous nonequilibrium density gradient ultracentrifugation technique was devised to isolate a series of fractions containing progressively smaller lipoproteins. Successive fractions showed progressive enrichment in cholesteryl-esters, depletion of triglyceride, slower migration on agarose, and depletion of apo E and the C apolipoproteins relative to apo B. The IDL-1 and IDL-2 subspecies appeared to represent two distributions of lipoproteins overlapping in size (particle diameter 280-300 A and 268-284 A, respectively) and buoyant density (d = 1.008-1.022 g/ml and d = 1.013-1.028 g/ml, respectively). Plasma from two patients with dysbetalipoproteinemia showed predominant increases in fractions normally containing small VLDL and IDL-1, while patients with severe hypertriglyceridemia had increases primarily in levels of larger VLDL. Heterogeneity of lipoprotein precursors could account for the discrete subspecies of LDL observed in human plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942562     DOI: 10.1161/01.atv.6.1.79

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  7 in total

Review 1.  The physiology of lipoproteins.

Authors:  Thomas N Tulenko; Anne E Sumner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance.

Authors:  E J Parks; R M Krauss; M P Christiansen; R A Neese; M K Hellerstein
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

3.  Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; H N Ginsberg; R M Krauss; F T Lindgren
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 4.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

5.  Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid.

Authors:  B Frei; T M Forte; B N Ames; C E Cross
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

6.  Prostacyclin Affects the Relation Between Brain Interstitial Glycerol and Cerebrovascular Pressure Reactivity in Severe Traumatic Brain Injury.

Authors:  Lars-Owe D Koskinen; Nina Sundström; Linda Hägglund; Anders Eklund; Magnus Olivecrona
Journal:  Neurocrit Care       Date:  2019-12       Impact factor: 3.210

7.  Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.

Authors:  Henry N Ginsberg; Chris J Packard; M John Chapman; Jan Borén; Carlos A Aguilar-Salinas; Maurizio Averna; Brian A Ference; Daniel Gaudet; Robert A Hegele; Sander Kersten; Gary F Lewis; Alice H Lichtenstein; Philippe Moulin; Børge G Nordestgaard; Alan T Remaley; Bart Staels; Erik S G Stroes; Marja-Riitta Taskinen; Lale S Tokgözoğlu; Anne Tybjaerg-Hansen; Jane K Stock; Alberico L Catapano
Journal:  Eur Heart J       Date:  2021-12-14       Impact factor: 29.983

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.